<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2025-18-3-121-126</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1888</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR OPHTHALMOLOGY PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Офтальмологические осложнения противоопухолевой терапии у пациентов с онкологическими заболеваниями различной локализации</article-title><trans-title-group xml:lang="en"><trans-title>Ophthalmological complications of antitumor therapy in patients with oncological diseases of various localizations</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0859-5435</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Матненко</surname><given-names>Т. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Matnenko</surname><given-names>T. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Юрьевна Матненко — канд. мед. наук, доцент, доцент кафедры офтальмологии</p><p>ул. Ленина, д. 12, Омск, 644099</p></bio><bio xml:lang="en"><p>Tatiana Yu. Matnenko — Cand. of Med. Sci., associate professor, chair of Ophthalmology</p><p>12, Lenina St., Omsk, 644099</p></bio><email xlink:type="simple">tm501@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8190-4121</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебедев</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedev</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Иванович Лебедев — д-р мед. наук, профессор, заведующий кафедрой офтальмологии</p><p>ул. Ленина, д. 12, Омск, 644099</p></bio><bio xml:lang="en"><p>Oleg  I.  Lebedev   —   Dr.   of   Med.   Sci.,   professor,   head   of   chair of ophthalmology</p><p>12, Lenina St., Omsk, 644099</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наурузбаева</surname><given-names>С. Ж.</given-names></name><name name-style="western" xml:lang="en"><surname>Nauruzbaeva</surname><given-names>S. Zh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сабина Жанатовна Наурузбаева — врач-офтальмолог</p><p>ул. Сейфуллина, д. 9/1, Астана, 010000</p></bio><bio xml:lang="en"><p>Sabina Zh. Nauruzbaeva — ophthalmologist, ORCID 0009-0002-6604-8245 1 Kamchatka Regional Oncological Dispensary</p><p>9/1, Seifullina St., Astana, 010000</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-3388-5457</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Овчинникова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovchinnikova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ксения Александровна Овчинникова — врач-ординатор кафедры офтальмологии</p><p>ул. Ленина, д. 12, Омск, 644099</p></bio><bio xml:lang="en"><p>Ksenija A. Ovchinnikova — resident physician, chair of ophthalmology</p><p>12, Lenina St., Omsk, 644099</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-6793-2966</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Анатольевич Соколов — врач-онколог, торакальный хирург, Камчатский краевой онкологический диспансер, главный врач, МЦ «ОРМЕДИУМ»</p><p>д. 15, Петропавловск-Камчатский, 683024, </p><p>Камчатский край, ул. Циолковского, д. 1, Петропавловск-Камчатский, 683009</p></bio><bio xml:lang="en"><p>Sergei A. Sokolov — oncologist, thoracic surgeon, Kamchatka Regional Oncological Dispensary, chief physician, LLC MC “ORMEDIUM”</p><p>15, Lukashevskogo St., Petropavlovsk-Kamchatsky, 683024,</p><p>1, Tsiolkovsky St., Petropavlovsk-Kamchatsky, 683009</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ТОО «Клиника микрохирургии глаза “Optima”»</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>TOO Clinic of Eye Microsurgery “Optima”</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Камчатский краевой онкологический диспансер;&#13;
МЦ «ОРМЕДИУМ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kamchatka Regional Oncological Dispensary;&#13;
LLC MC “ORMEDIUM”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>09</month><year>2025</year></pub-date><volume>18</volume><issue>3</issue><fpage>121</fpage><lpage>126</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Матненко Т.Ю., Лебедев О.И., Наурузбаева С.Ж., Овчинникова К.А., Соколов С.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Матненко Т.Ю., Лебедев О.И., Наурузбаева С.Ж., Овчинникова К.А., Соколов С.А.</copyright-holder><copyright-holder xml:lang="en">Matnenko T.Y., Lebedev O.I., Nauruzbaeva S.Z., Ovchinnikova K.A., Sokolov S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1888">https://roj.igb.ru/jour/article/view/1888</self-uri><abstract><p>Современный уровень помощи пациентам с онкологическими заболеваниями позволяет достичь ремиссии или выздоровления в случаях, считавшихся ранее неизлечимыми. Вместе с тем накапливается опыт возможных побочных эффектов, влияющих на качество жизни пациентов. За последние годы в литературе описаны осложнения со стороны органа зрения, затрагивающие как передний отрезок глаза, так и сетчатку и зрительный нерв.</p><p>Цель работы — проанализировать особенности побочных эффектов противоопухолевой терапии онкологических заболеваний различной локализации со стороны органа зрения на клинических примерах. Описаны 2 случая осложнений химиотерапии: при раке молочной железы с использованием тамоксифена, при диффузной В-клеточной лимфоме с поражением костного мозга на фоне терапии винкристином. Побочные эффекты тамоксифена характеризовались снижением остроты зрения в сочетании с кристаллическими отложениями на сетчатке по типу фигуры звезды, отеком диска зрительного нерва. Использование стероидной терапии оказало положительный эффект, острота зрения повысилась. Применение винкристина во втором клиническом примере привело к поражению зрительного нерва по типу папиллита. Проведенная терапия не дала повышения зрения. Осложнения, связанные с терапией винкристином, являются дозозависимыми, своевременная отмена препарата могла сохранить зрительные функции.</p><p>Заключение. Наиболее токсичными противоопухолевыми препаратами для органа зрения являются алкилирующие агенты, антиметаболиты, ингибиторы митоза, гормональные средства, моноклональные антитела, ингибиторы протеинкиназы. Взаимодействие онкологов и офтальмологов может сохранить высокое качество жизни пациентам с онкологическими заболеваниями при своевременной коррекции терапии.</p></abstract><trans-abstract xml:lang="en"><p>The current level of care for patients with cancer allows them to achieve remission or recovery in cases previously considered incurable. At the same time, the experience of possible side effects affecting the quality of life of patients is accumulating. In recent years, complications from the organ of vision have been described in the literature, affecting both the anterior segment of the eye, as well as the retina and optic nerve. The aim of the work is to analyze the features of the side effects of antitumor therapy of oncological diseases of various localization on the part of the organ of vision using clinical examples. Two cases of chemotherapy complications have been described: in breast cancer using tamoxifen, in diffuse B-cell lymphoma with bone marrow damage during vincristine therapy. The side effects of tamoxifen were characterized by a decrease in visual acuity in combination with crystalline deposits on the retina by the type of star shape, edema of the optic disc. The use of steroid therapy had a positive effect, visual acuity increased. The use of vincristine in the second clinical example led to damage to the optic nerve by the type of papillitis. The therapy did not lead to an increase in vision. The complications associated with vincristine therapy are dosedependent, timely withdrawal of the drug could preserve visual functions. Conclusion: the most toxic antitumor drugs for the organ of vision are alkylating agents, antimetabolites, mitosis inhibitors, hormonal agents, monoclonal antibodies, protein kinase inhibitors. The interaction between oncologists and ophthalmologists can maintain a high quality of life for patients with cancer.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>тамоксифен</kwd><kwd>нейроретинит</kwd><kwd>фигура звезды</kwd><kwd>нейрооптикопатия</kwd><kwd>В-клеточная лимфома</kwd><kwd>винкристин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>tamoxifen</kwd><kwd>neuroretinitis</kwd><kwd>star figure</kwd><kwd>neuroopticopathy</kwd><kwd>B-cell lymphoma</kwd><kwd>vincristine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Asencio-Durán M, Fernández-Gutiérrez E, Larrañaga-Cores M, et al. Ocular side effects of oncological therapies: Review. Archivos de la Sociedad Española de Oftalmología (English Edition), 2024; 99 (3): 109–32. https://doi.org/10.1016/j.oftale.2023.11.003</mixed-citation><mixed-citation xml:lang="en">Asencio-Durán M, Fernández-Gutiérrez E, Larrañaga-Cores M, et al. Ocular side effects of oncological therapies: Review. Archivos de la Sociedad Española de Oftalmología (English Edition), 2024; 99 (3): 109–32. https://doi.org/10.1016/j.oftale.2023.11.003</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Муфтахова Г.М., Грачёв Н.С., Ушакова Т.Л., Горбунова Т.В., Першин Б.С. Поздние эффекты со стороны органов слуха и зрения. Российский журнал детской гематологии и онкологии. 2020; 3 (7): 150–6.</mixed-citation><mixed-citation xml:lang="en">Muftakhova G.M., Grachev N.S., Ushakova T.L., Gorbunova T.V., Pershin B.S. Late effects on the organs of hearing and vision. Russian journal of pediatric hematology and oncology. 2020; 3 (7): 150–6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ma J, Pazo EE, Zou Z, Jin F. Prevalence of symptomatic dry eye in breast cancer patients under going systemic adjuvant treatment: Across-sectional study. The breast. 2020; 53: 164–71. https://doi.org/10.1016/j.breast.2020.07.009</mixed-citation><mixed-citation xml:lang="en">Ma J, Pazo EE, Zou Z, Jin F. Prevalence of symptomatic dry eye in breast cancer patients under going systemic adjuvant treatment: Across-sectional study. The breast. 2020; 53: 164–71. https://doi.org/10.1016/j.breast.2020.07.009</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Салмон Д.Ф. Клиническая офтальмология Кански. Систематизированный подход. Нероев В.В., ред. 9-е изд. Москва: ООО «Издательство «Медицинское информационное агентство». 2023: 955–7.</mixed-citation><mixed-citation xml:lang="en">Salmon D.F. Kansky’s Clinical Ophthalmology. A Systematic Approach. Neroev V. V., ed. 9th ed. Moscow: OOO “Izdatelstvo “Medical Information Agency”. 2023: 955–7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Алтынбаева Г.Р., Азаматова Г.А., Гильванова А.А., Хайдаров И.Х. Опыт лечения вторичного синдрома сухого глаза, вызванного эктропионом век на фоне химиотерапии, у пациента со злокачественным новообразованием прямой кишки. Саратовский научно-медицинский журнал. 2021; 17 (2): 266–8.</mixed-citation><mixed-citation xml:lang="en">Altynbaeva G.R., Azamatova G.A., Gilvanova A.A., Khaidarov I. Kh. Experience in treating secondary dry eye syndrome caused by ectropion of the eyelids during chemotherapy in a patient with a malignant neoplasm of the rectum. Saratov scientific medical journal. 2021; 17 (2): 266–8 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Куницкая Н.А. Развитие осложненного синдрома сухого глаза на фоне лечения злокачественного новобразования легкого: случай из практики. Magyar Tudomanyos Journal. 2020; 46: 19–21.</mixed-citation><mixed-citation xml:lang="en">Kunitskaya N.A. Development of complicated dry eye syndrome during treatment of lung malignancy: A case from practice. Magyar Tudomanyos Journal. 2020; 46: 19–21 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: What do we need to know as ophthalmologists? Acta Ophthalmol. 2013, 91, 604–9. https://doi.org/10.1111/j.1755-3768.2012.02518.x</mixed-citation><mixed-citation xml:lang="en">Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: What do we need to know as ophthalmologists? Acta Ophthalmol. 2013, 91, 604–9. https://doi.org/10.1111/j.1755-3768.2012.02518.x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Singh P, Singh A. Ocular adverse effects of anti-cancer chemotherapy. Journal of cancer therapeutics and research. January 2012; 1 (1): 5. doi: 10.7243/2049-7962-1-5</mixed-citation><mixed-citation xml:lang="en">Singh P, Singh A. Ocular adverse effects of anti-cancer chemotherapy. Journal of cancer therapeutics and research. January 2012; 1 (1): 5. doi: 10.7243/2049-7962-1-5</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">DiStaso F, Gattazzo I, Taurelli Salimbeni B, et al. Treatment of capecitabine corneal side effects with autologous blood-derived serum eye drops. In Vivo. 2021 May-Jun; 35 (3): 1881–4. https://doi.org/10.21873/invivo.12451</mixed-citation><mixed-citation xml:lang="en">DiStaso F, Gattazzo I, Taurelli Salimbeni B, et al. Treatment of capecitabine corneal side effects with autologous blood-derived serum eye drops. In Vivo. 2021 May-Jun; 35 (3): 1881–4. https://doi.org/10.21873/invivo.12451</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Qian Chen, Chaoyi Feng, Chuanbin Sun, et al. Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma — a case report of a Chinese patient. Am J Ophthalmol Case Rep. 2022 Jan 29; 25: 101370. https://doi.org/10.1016/j.ajoc.2022.101370</mixed-citation><mixed-citation xml:lang="en">Qian Chen, Chaoyi Feng, Chuanbin Sun, et al. Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma — a case report of a Chinese patient. Am J Ophthalmol Case Rep. 2022 Jan 29; 25: 101370. https://doi.org/10.1016/j.ajoc.2022.101370</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985 Dec; 3 (12): 1683–9. doi: 10.1200/JCO.1985.3.12.1683</mixed-citation><mixed-citation xml:lang="en">Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985 Dec; 3 (12): 1683–9. doi: 10.1200/JCO.1985.3.12.1683</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Stoicescu EA, Iancu RC, Popa Cherecheanu A, Iancu G. Ocular adverse effects of anti-cancer chemotherapy. J Med Life. 2023 Jun; 16 (6): 818–21. https://doi.org/10.25122/jml-2023-0041</mixed-citation><mixed-citation xml:lang="en">Stoicescu EA, Iancu RC, Popa Cherecheanu A, Iancu G. Ocular adverse effects of anti-cancer chemotherapy. J Med Life. 2023 Jun; 16 (6): 818–21. https://doi.org/10.25122/jml-2023-0041</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sodhi M, Yeung SN, Maberley D, Mikelberg F, Etminan M. Risk of ocular adverse events with Taxane-based chemotherapy. JAMA Ophthalmol. 2022 Sep 1; 140 (9): 880–4. https://doi.org/10.1001/jamaophthalmol.2022.3026</mixed-citation><mixed-citation xml:lang="en">Sodhi M, Yeung SN, Maberley D, Mikelberg F, Etminan M. Risk of ocular adverse events with Taxane-based chemotherapy. JAMA Ophthalmol. 2022 Sep 1; 140 (9): 880–4. https://doi.org/10.1001/jamaophthalmol.2022.3026</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L. [Tamoxifen retinopathy: A case series of clinical and functional data]. Ophthalmologe. 2008; 105: 544–9. https://doi.org/10.1007/s00347-007-1677-8</mixed-citation><mixed-citation xml:lang="en">Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L. [Tamoxifen retinopathy: A case series of clinical and functional data]. Ophthalmologe. 2008; 105: 544–9. https://doi.org/10.1007/s00347-007-1677-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lee WH, You SK, Lee YH. Bilateral optic neuropathy following vincristine chemotherapy: A case report with description of multimodal imaging findings. Medicine (Baltimore). 2021 Mar 5; 100 (9): e24706. https://doi.org/10.1097/md.0000000000024706</mixed-citation><mixed-citation xml:lang="en">Lee WH, You SK, Lee YH. Bilateral optic neuropathy following vincristine chemotherapy: A case report with description of multimodal imaging findings. Medicine (Baltimore). 2021 Mar 5; 100 (9): e24706. https://doi.org/10.1097/md.0000000000024706</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
